Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MRNS NASDAQ:ONCY NYSE:PLX NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.94 million shs260 shsONCYOncolytics Biotech$1.14-4.2%$0.72$0.33▼$1.53$112.20M1.071.48 million shs866,625 shsPLXProtalix BioTherapeutics$1.55-3.1%$1.52$0.82▼$3.10$123.39M-0.23883,601 shs394,892 shsSKYESkye Bioscience$4.01-8.0%$3.13$1.14▼$7.47$135.05M1.951.15 million shs260,808 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-62.90%ONCYOncolytics Biotech-4.03%-4.80%+86.81%+104.01%+16.67%PLXProtalix BioTherapeutics+1.27%+11.89%+18.52%-45.11%+39.13%SKYESkye Bioscience+12.37%+18.16%+51.86%+143.58%-28.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRNSMarinus Pharmaceuticals2.1089 of 5 stars3.20.00.04.20.01.70.6ONCYOncolytics Biotech1.5665 of 5 stars3.43.00.00.01.50.00.0PLXProtalix BioTherapeutics2.9986 of 5 stars3.53.00.00.02.40.01.9SKYESkye Bioscience1.8206 of 5 stars3.54.00.00.01.10.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideONCYOncolytics Biotech 2.75Moderate Buy$4.33280.12% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00867.74% UpsideSKYESkye Bioscience 3.00Buy$16.60313.97% UpsideCurrent Analyst Ratings BreakdownLatest MRNS, PLX, SKYE, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/APLXProtalix BioTherapeutics$59.76M2.06$0.09 per share17.80$0.47 per share3.30SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.04N/A5.00N/A-21.03%-30.89%-11.74%N/ASKYESkye Bioscience-$26.57M-$0.820.00N/AN/AN/A-53.92%-48.58%N/ALatest MRNS, PLX, SKYE, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ONCYOncolytics Biotech-$0.10N/AN/AN/AN/AN/A5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/A5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRNSMarinus PharmaceuticalsN/A1.661.47ONCYOncolytics BiotechN/A3.203.20PLXProtalix BioTherapeuticsN/A1.981.27SKYESkye BioscienceN/A11.8511.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRNSMarinus Pharmaceuticals98.80%ONCYOncolytics Biotech6.82%PLXProtalix BioTherapeutics16.53%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipMRNSMarinus Pharmaceuticals5.46%ONCYOncolytics Biotech0.10%PLXProtalix BioTherapeutics6.50%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableONCYOncolytics Biotech3094.28 million94.19 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableSKYESkye Bioscience1130.98 million29.58 millionOptionableMRNS, PLX, SKYE, and ONCY HeadlinesRecent News About These CompaniesSKYE Stock Price Quote | MorningstarJuly 11, 2025 | morningstar.comMSkye Bioscience, Inc. (SKYE) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSkye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a DataJuly 6, 2025 | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Rating of "Buy" by BrokeragesJuly 3, 2025 | marketbeat.comPositive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past yearJune 25, 2025 | finance.yahoo.comSkye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...June 24, 2025 | manilatimes.netMSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - MorningstarJune 24, 2025 | morningstar.comMSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - NasdaqJune 24, 2025 | nasdaq.comSkye Bioscience (NASDAQ:SKYE) Receives "Market Outperform" Rating from JMP SecuritiesJune 24, 2025 | marketbeat.comSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity TreatmentJune 23, 2025 | quiverquant.comQSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific SessionsJune 23, 2025 | globenewswire.comSkye confirms phase 2 data on nimacimab for obesity expected later this yearJune 19, 2025 | msn.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific SessionsJune 17, 2025 | finance.yahoo.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific SessionsJune 17, 2025 | globenewswire.com3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesMay 23, 2025 | zacks.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comQ&A: Next wave of obesity drugs may ‘afford a lot of advantages’May 20, 2025 | healio.comHArecor shares climb 18% on collaboration with Skye BioscienceMay 19, 2025 | lse.co.ukArecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate NimacimabMay 19, 2025 | cambridgenetwork.co.ukCSkye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate NimacimabMay 19, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRNS, PLX, SKYE, and ONCY Company DescriptionsMarinus Pharmaceuticals NASDAQ:MRNSMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Oncolytics Biotech NASDAQ:ONCY$1.14 -0.05 (-4.20%) Closing price 04:00 PM EasternExtended Trading$1.11 -0.03 (-2.63%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Protalix BioTherapeutics NYSE:PLX$1.55 -0.05 (-3.13%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Skye Bioscience NASDAQ:SKYE$4.01 -0.35 (-8.03%) Closing price 04:00 PM EasternExtended Trading$4.14 +0.13 (+3.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
